These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6683651)

  • 1. The influence of antiserotonin treatment with ketanserin on the pulmonary lodgement of circulating tumour cells in normal and traumatized rats.
    Skolnik G; Ivarsson L; Bagge U
    Eur J Cancer Clin Oncol; 1983 Jun; 19(6):843-6. PubMed ID: 6683651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of thrombocytopenia and antiserotonin treatment on the lodgement of circulating tumor cells. A vital fluorescence microscopic, electron microscopic and isotope study in the rat.
    Skolnik G; Ericson LE; Bagge U
    J Cancer Res Clin Oncol; 1983; 105(1):30-7. PubMed ID: 6833337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of calcium channels and serotonin (5-HT2) receptors for tumour cell lodgement in the liver.
    Skolnik G; Bagge U; Blomqvist G; Djärv L; Ahlman H
    Clin Exp Metastasis; 1989; 7(2):169-74. PubMed ID: 2537694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of platelet-released 5-HT in tumor cell lodgement.
    Skolnik G; Bagge U; Blomqvist G; Dahlström A; Ahlman H
    J Surg Res; 1985 Jun; 38(6):559-67. PubMed ID: 2861307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of 5-HT for tumor cell lodgement in the liver.
    Skolnik G; Bagge U; Dahlström A; Ahlman H
    Int J Cancer; 1984 Apr; 33(4):519-23. PubMed ID: 6368410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies on mechanisms involved in metastasis formation from circulating tumor cells. Factors influencing tumor cell lodgement during normal and post-traumatic conditions.
    Skolnik G; Alpsten M; Ivarsson L
    J Cancer Res Clin Oncol; 1980; 97(3):249-56. PubMed ID: 7440626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of trauma, Dextran 1000, and Dextran 40 on the lodgement of circulating tumor cells.
    Skolnik G; Alpsten M; Ivarsson L
    J Cancer Res Clin Oncol; 1980; 97(3):241-8. PubMed ID: 6160158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug treatment of claudication: vasodilators, hemorrheologic agents, and antiserotonin drugs.
    Taylor LM; Porter JM
    J Vasc Surg; 1986 Feb; 3(2):374-81. PubMed ID: 2935646
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.
    Stranden E; Roald OK; Krohg K
    Br Med J (Clin Res Ed); 1982 Oct; 285(6348):1069-71. PubMed ID: 6812750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ketanserin in primary aldosteronism.
    Mantero F; Rocco S; Opocher G; Armanini D; Boscaro M; D'Agostino D
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S172-5. PubMed ID: 2412045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The arrest of circulating tumor cells in the liver microcirculation. A vital fluorescence microscopic, electron microscopic and isotope study in the rat.
    Bagge U; Skolnik G; Ericson LE
    J Cancer Res Clin Oncol; 1983; 105(2):134-40. PubMed ID: 6826636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon.
    Bounameaux HM; Hellemans H; Verhaeghe R; Dequeker J
    J Cardiovasc Pharmacol; 1984; 6(5):975-6. PubMed ID: 6209510
    [No Abstract]   [Full Text] [Related]  

  • 14. Metastasis formation after intravenous tumour cell injection in thrombocytopenic rats.
    Ivarsson L
    Eur Surg Res; 1976; 8(1):51-60. PubMed ID: 1248501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin, dextran 1000 and metastasis formation after I.V. tumour cell injection in dextran non-sensitive rats.
    Ivarsson L; Rudenstam CM
    Br J Cancer; 1975 Oct; 32(4):502-8. PubMed ID: 1212413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.
    Seibold JR; Jageneau AH
    Arthritis Rheum; 1984 Feb; 27(2):139-46. PubMed ID: 6365102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketanserin: a selective serotonin antagonist.
    Lancet; 1982 Oct; 2(8303):859. PubMed ID: 6126719
    [No Abstract]   [Full Text] [Related]  

  • 18. Arterial occlusion reduces tumour cell lodgement in the rat liver.
    Blomqvist G; Bagge U; Skolnik G
    Eur J Cancer Clin Oncol; 1988 Oct; 24(10):1573-8. PubMed ID: 3208801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raynaud's disease: a new therapeutic approach with a 5-HT2 receptors blocker.
    Allegra C; Tonelli V; Bonifacio M; Mari A; Assogna G
    Boll Chim Farm; 1985 Oct; 124(10):121S-124S. PubMed ID: 2935173
    [No Abstract]   [Full Text] [Related]  

  • 20. Alpha 1 antagonistic and antiserotoninergic action during administration of ketanserin.
    Vermylen J; Fiocchi R; Fagard R; Lijnen P; Staessen J; Amery A
    Br Med J (Clin Res Ed); 1983 Nov; 287(6404):1551-2. PubMed ID: 6139140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.